United Therapeutics Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how much money the company made and spent in recent months.
Detailed quarterly report reveals company assets, liabilities, and detailed financial performance.
New board members help oversee company decisions and bring experience that can affect company direction.
New stock plan lets company reward employees and directors with stock, aligning their interests with company success.
Quarterly earnings show how much money the company made and spent in the first three months of 2026.
Detailed quarterly report reveals company assets, liabilities, and detailed financial performance for Q1.
Successful drug trial results can increase company value and lead to more patient treatments and revenue.
Stocky reads United Therapeutics Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
United Therapeutics Corporation's most recent tracked filing was a 8-K on 5 Aug 2026: Reports second quarter 2026 earnings on August 5.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.